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followed by mandatory 90-day (36.85%, 35.51%) and 30-day
retail program (33.73%, 32.41%) in both claims level and
patient level, respectively. However, only the GDR differences
between voluntary 90-day retail program and 30-day retail
program were found to be statistically signiﬁcant for all three
therapeutic classes at both claim and patient level (P < 0.05).
CONCLUSION: The study showed comparable results indicat-
ing that there were no drastic difference in the utilization of
generic drug by claims and patients between mandatory 90-day
retail program and 30-day retail program. However, voluntary
90-day retail program showed a signiﬁcantly higher share of
generic utilization than 30-day retail program.
PHP17
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OBJECTIVES: To estimate the prevalence of clinically important
potential drug-drug interactions (DDIs) among residents of
Regione Emilia Romagna (RER), Italy. METHODS: We con-
ducted a retrospective cohort study using the 2004 outpatient
prescription claims database of RER, which was linked to the
2004 demographic ﬁle of 4,222,165 RER residents. Using a pre-
viously published list of clinically important potential DDIs as
framework, we identiﬁed 11 potential DDIs that could be cap-
tured through the RER database because both drugs were reim-
bursed by the 2004 Italian National Formulary. A potential DDI
was deﬁned as the presence of a minimum 5-day overlap in days
supply for each of the drugs in an interacting pair. The World
Health Organization Anatomical Therapeutic Classiﬁcation/
Deﬁned Daily Dose System was used to determine a proxy
measure of days supply for each drug. The one-year prevalence
of each potential DDI was quantiﬁed at the patient level.
RESULTS: In 2004, the 11 potential DDIs occurred 7,379 times
in 6,681 RER residents, yielding a one-year prevalence of 158.2
cases per 100,000 individuals. The mean age of those exposed
to potential DDIs was 74.1 (SD = 10.8) years and about 52%
were female. Of those exposed, 559 (8.4%) were exposed to 2
potential DDIs and 64 (1.0%) were exposed to at least 3 poten-
tial DDIs. The most commonly identiﬁed potentially interacting
medication pairs were warfarin and nonsteroidal anti-inﬂamma-
tory drugs (5,616 cases), theophylline/aminophylline and the 
ﬂuoroquinolones ciproﬂoxacin and ﬂuvoxamine (759), warfarin
and barbiturates (530), and warfarin and ﬁbric acids (339).
CONCLUSION: To our knowledge, this is the ﬁrst large popu-
lation-based study in Italy documenting the prevalence of poten-
tial DDIs. A substantial number of clinically important potential
DDIs were identiﬁed, particularly among warfarin users. DDIs
are predictable, hence preventable. Awareness of the most com-
monly occurring potential DDIs can help practitioners prevent
coadministration of these potentially dangerous medication 
combinations.
PHP18
BENEFICIARY OUT-OF-POCKET:A CROSS-SECTIONAL PILOT
STUDY IN THE SAUDI MINISTRY OF HEALTH HOSPITAL
OUTPATIENT CLINICS
Alkelya MA
Saudi MOI, Directorate of Medical Services, Makkah, Makkah, Saudi
Arabia
OBJECTIVES: To estimate the beneﬁciary’s out-of-pocket spend-
ing to ﬁll their prescriptions in 2003 at the Saudi Ministry of
Health (MOH) hospital outpatient clinics. METHODS: A non-
randomized sample of 19 hospitals participated in a study inves-
tigating the inﬂuence of pharmacy and therapeutics (P&T) com-
mittee and pharmacy information system (PIS) on patients’
access to and utilization of prescription drugs. These hospitals
were selected deliberately to represent different levels of PIS and
P&T committee characteristics based on the results of a descrip-
tive study of all 127 non-specialized MOH hospitals. Systematic
sampling was used to audit 150 patients prescription papers
(orders) from each hospital outpatient pharmacy. The cost esti-
mates based on community pharmacy market price. RESULTS:
Of 2850 audited patient records, only 202(7.1%) had a free
access rate less than 100 percent and have to pay out-of-pocket.
The mean of out-of-pocket spending is $16.5 (s = 34.4)to ﬁll pre-
scriptions. Patients diagnosed with cardiovascular diseases or
multiple diagnosis are more likely to pay out-of-pocket. Patients
with chronic disease have an average of $24.1 monthly spend-
ing and only 1.8% of them have to pay more than $100 monthly.
The spending rate is signiﬁcantly correlated with non-formulary
drugs (r = 0.48) and also associated with a single source brand
names. CONCLUSION: The data revealed a high rate of free
access to prescription drug for MOH beneﬁciaries and an accept-
able (<16.5 US dollar) out-of-pocket spending for 98% of the
patients who paid out-of-pocket. Although, there are multiple
and alternative sources for MOH beneﬁciaries to avoid out-of-
pocket spending, there is still vulnerable group that dose not
have alternative source and might have a potential to not offered
to pay out-of-pocket. MOH may use its resources and consider
this group to ﬁll their prescriptions with minimum cost by using
the hospital social work program to identify this group.
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OBJECTIVES: Medication adherence is a major obstacle to
overcome when treating chronic medical conditions. Many
factors can inﬂuence how well a medication regimen is complied
with, including patient demographics such as race. The aim of
this study was to determine how race can affect medication
adherence in Medicaid-enrolled patients with chronic disease.
METHODS: We examined the association between race and
controller medication adherence in confounder adjusted multi-
variate analyses on data from 3 retrospective cohorts enrolled in
the North Carolina Medicaid program. These cohorts included
patients with primary diagnoses of asthma (n = 710), type 2 dia-
betes (n = 2655), and psoriasis (n = 186). The data for these
studies was extrapolated from the North Carolina Medicaid
claims and eligibility ﬁles and patients were followed up for a
minimum of two years. RESULTS: The results were mixed across
disease states. In patients with type 2 we found that medication
adherence rates (using medication possession ratios) for oral
antidiabetics was signiﬁcantly higher for whites [59%] as com-
pared to African Americans [54%] (p < 0.05). Similarly, in
patients with asthma, we found that African American patients
were 65% less likely to have the recommended medication pos-
session rate of at least 80% [RR: 0.35, 95% CI: 0.15–0.81].
There were no signiﬁcant patient differentials in controller med-
ication adherence by race in patients with psoriasis. CONCLU-
SION: The results were mixed across disease states. In patients
with type 2 we found that medication adherence rates (using
medication possession ratios) for oral antidiabetics was signiﬁ-
cantly higher for whites [59%] as compared to African Ameri-
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cans [54%] (p < 0.05). Similarly, in patients with asthma, we
found that African American patients were 65% less likely to
have the recommended medication possession rate of at least
80% [RR: 0.35, 95% CI: 0.15–0.81]. There were no signiﬁcant
patient differentials in controller medication adherence by race
in patients with psoriasis.
PHP20
IMPACT OF POLYPHARMACY MEDICATION THERAPY
MANAGEMENT PROGRAM (MTMP) ON DRUG EXPENDITURES
IN MEDICARE PART D POPULATION
Miller SA1, Lou Y1, Mu Y1, Huang Z2, Lee KY2, Bertram CT2
1Walgreens, Deerﬁeld, IL, USA, 2Walgreens Health Services, Deerﬁeld,
IL, USA
OBJECTIVES: To assess the impact of polypharmacy inter-
vention on drug cost in the Medicare Part D population.
METHODS: This is a case-control study, based on 2006
Medicare Part D population. The case group contains cases
which have received Polypharmacy interventions, whereas the
control group contains cases which have not been intervened
upon. Per member per month (PMPM) drug savings were cal-
culated as the difference between the projected post-intervention
drug cost of the case group and the actual post-intervention drug
cost of the case group. The projected post-intervention drug cost
is based on the pre-post intervention percent change in the
PMPM drug cost of the control group. RESULTS: There were
6050 Polypharmacy cases, of which 3442 were intervened on.
The remainder served as the control group. The actual post-inter-
vention PMPM drug cost for the case group was $611 and the
projected post-intervention PMPM drug cost for the same group
was $663, a difference of $52, representing $52 PMPM drug
cost savings. CONCLUSION: Polypharmacy MTMP may not
only help improve therapeutic outcomes through improved med-
ication use, but may also reduce overall health cost. The present
study showed signiﬁcant pharmacy savings as a result of
Polypharmacy intervention. This study did not address medical
cost savings due to the lack of longitudinal medical claim data.
However it would not be unreasonable to assume Polypharmacy
intervention could signiﬁcantly reduce medical cost.
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OBJECTIVES: State Medicaid programs vary drastically in terms
of their prescription drug expenditure per recipient. Prior research
has attempted to explain these variations by identifying potential
determinants of drug expenditure. However, analyses in the past
have been restricted to a few variables and several other poten-
tial determinants and their interactions have not been investi-
gated. Objectives of this study were: a) To identify potential
determinants of Medicaid per capita drug expenditures based on
an established comprehensive model for health services utiliza-
tion; and b) to test impacts of the identiﬁed determinants on per
capita drug expenditures. METHODS: This study employs
Andersen’s Behavior Model of Health Services Utilization to iden-
tify potential determinants of pharmaceutical expenditures in
state Medicaid programs using publicly available data. A struc-
ture equation model was built to test relationships among the
latent constructs of policy, access, predisposing characteristics,
enabling resources, and need for health care, and their inﬂuence
on drug utilization. RESULTS: “Predisposing characteristics”
were found to impact “enabling resources” which, in turn, was
found to signiﬁcantly impact drug utilization. Among the
observed variables, “access to hospitals” and “access to primary
care physicians” signiﬁcantly described “health care resources”;
“risk of diseases” described “need for health care”; and “poverty”
described the latent construct of “enabling resources”. The
“policy” construct was not described adequately by the indica-
tor variables. CONCLUSION: Based on the study results, we con-
clude that Medicaid policy and program interventions, as
described in this model, do not inﬂuence drug costs signiﬁcantly.
Population characteristics like predispositions and enabling
resources determine drug costs in the state Medicaid programs.
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OBJECTIVES: To examine the impact of consumer driven health
plans (CDHPs) on pharmacy and medical utilization, health care
and pharmacy expenditures. METHODS: We utilized enroll-
ment, medical and pharmacy claims data from a national
employer who switched from offering a traditional PPO based
plan (i.e., the “pre” period in 2004) to only offering CDHP
options to their employees in 2005 (i.e., the “post” period).
Patients with select chronic diseases including diabetes and
asthma were included for analyses. Outcomes measured included
total number of prescriptions, disease based medication adher-
ence (estimated by the Medication Possession Ratio (MPR) with
80% or higher classiﬁed as being “adherent”), ER, inpatient and
outpatient visits and pharmacy and health care expenditures.
GEE (Generalized Estimating Equations) for repeated measures
were used because there are 2 correlated observations on each
subject in the dataset adjusting for age, gender, co-morbid risk
scores, family size, coverage status and migration patterns
between the CDHP options. Outcomes variables that were char-
acterized by a large proportion of 0s and extreme right skew
were analyzed using two-part models with logarithmic transfor-
mation of the non-zero observations and a smearing re-trans-
formation. RESULTS: Preliminary results show that for CDHP
switchers there was a reduction in most measures: outpatient
visits reduced by 22%, total number of prescriptions decreased
by 25%, medical and pharmacy expenditures reduced by 22%
and 24% respectively. Individuals were 37% less likely to be
adherent with their drug therapy across all disease states in a
CDHP compared to their adherence in a PPO plan. There were
no appreciable differences in ER and inpatient visits. CON-
CLUSION: Switching to a CDHP resulted in lower utilization of
some services and expenditures. Switching was also associated
with decrease inﬂuenced by CDHP beneﬁt design. CDHPs can
be a useful plan offering but plans should design interventions
to improve medication adherence.
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